7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Atrial Remodeling D064752 1 associated lipids
Vascular Calcification D061205 1 associated lipids
Angina, Stable D060050 2 associated lipids
Bisphosphonate-Associated Osteonecrosis of the Jaw D059266 1 associated lipids
Osteoporotic Fractures D058866 1 associated lipids
Peripheral Arterial Disease D058729 7 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Peri-Implantitis D057873 1 associated lipids
Primary Myelofibrosis D055728 6 associated lipids
Chronic Periodontitis D055113 1 associated lipids
Osteophyte D054850 2 associated lipids
Hyperphosphatemia D054559 1 associated lipids
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative D054438 1 associated lipids
No-Reflow Phenomenon D054318 2 associated lipids
Acute Coronary Syndrome D054058 11 associated lipids
Hypercalciuria D053565 4 associated lipids
Renal Insufficiency, Chronic D051436 9 associated lipids
Fractures, Bone D050723 4 associated lipids
Arteriolosclerosis D050379 1 associated lipids
Atherosclerosis D050197 85 associated lipids
Dyslipidemias D050171 7 associated lipids
Hashimoto Disease D050031 1 associated lipids
Hyperparathyroidism, Primary D049950 1 associated lipids
Diabetes Complications D048909 4 associated lipids
Hypertension, Pregnancy-Induced D046110 2 associated lipids
Scleroderma, Limited D045745 1 associated lipids
Glucose Metabolism Disorders D044882 3 associated lipids
Malnutrition D044342 6 associated lipids
Irritable Bowel Syndrome D043183 8 associated lipids
Mastocytoma D034801 3 associated lipids
Hearing Loss D034381 3 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Spondylarthropathies D025242 1 associated lipids
Spondylarthritis D025241 1 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Coronary Stenosis D023921 6 associated lipids
Carcinoma, Pancreatic Ductal D021441 6 associated lipids
Multiple Sclerosis, Relapsing-Remitting D020529 7 associated lipids
Multiple Sclerosis, Chronic Progressive D020528 3 associated lipids
Brain Infarction D020520 17 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Lithiasis D020347 2 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Tooth Ankylosis D020254 1 associated lipids
Venous Thrombosis D020246 11 associated lipids
Intracranial Hemorrhage, Traumatic D020198 1 associated lipids
Sleep Apnea, Obstructive D020181 9 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Hot Flashes D019584 5 associated lipids
Bone Marrow Neoplasms D019046 2 associated lipids
Myositis, Inclusion Body D018979 3 associated lipids
Sepsis D018805 11 associated lipids
Arthralgia D018771 8 associated lipids
Systemic Inflammatory Response Syndrome D018746 4 associated lipids
Breast Neoplasms, Male D018567 1 associated lipids
Bone Demineralization, Pathologic D018488 1 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Cholesteatoma, Middle Ear D018424 2 associated lipids
Foot Injuries D018409 1 associated lipids
Alphavirus Infections D018354 1 associated lipids
Hemangioma, Capillary D018324 1 associated lipids
Neoplasms, Squamous Cell D018307 1 associated lipids
Carcinoma, Neuroendocrine D018278 2 associated lipids
Carcinoma, Medullary D018276 2 associated lipids
Carcinoma, Lobular D018275 4 associated lipids
Carcinoma, Ductal, Breast D018270 19 associated lipids
Adrenocortical Adenoma D018246 1 associated lipids
Fibroma, Ossifying D018214 1 associated lipids
Giant Cell Tumor of Bone D018212 1 associated lipids
Lymphangioleiomyomatosis D018192 1 associated lipids
Bone Cysts, Aneurysmal D017824 2 associated lipids
Diabetic Foot D017719 1 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Microvascular Angina D017566 2 associated lipids
Aortic Aneurysm, Abdominal D017544 5 associated lipids
Myocardial Ischemia D017202 11 associated lipids
beta-Thalassemia D017086 5 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Carotid Stenosis D016893 15 associated lipids
POEMS Syndrome D016878 1 associated lipids
Pasteurellaceae Infections D016871 2 associated lipids
Bacteroidaceae Infections D016866 2 associated lipids
Leishmaniasis, Cutaneous D016773 6 associated lipids
Diabetes, Gestational D016640 8 associated lipids
Severe Combined Immunodeficiency D016511 1 associated lipids
Peripheral Vascular Diseases D016491 8 associated lipids
Bacteremia D016470 9 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Fractures, Stress D015775 2 associated lipids
Mammary Neoplasms, Animal D015674 27 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
HIV Infections D015658 20 associated lipids
Histiocytosis, Non-Langerhans-Cell D015616 4 associated lipids
Hyperostosis D015576 1 associated lipids
Arthritis, Psoriatic D015535 3 associated lipids
Leukemia, Lymphocytic, Chronic, B-Cell D015451 25 associated lipids
Weight Loss D015431 56 associated lipids
Weight Gain D015430 101 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Sudhoff H et al. [Expression of osteoclast stimulating and differentiating factors in a murine model of localized inflammatory bone resorption]. 2004 Laryngorhinootologie pmid:14740300
Findlay DM et al. The proliferation and phenotypic expression of human osteoblasts on tantalum metal. 2004 Biomaterials pmid:14741587
Theoleyre S et al. Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor kappaB ligand and MAPK. 2004 Biochim. Biophys. Acta pmid:14741739
Redlich K et al. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. 2004 Am. J. Pathol. pmid:14742260
Mogi M et al. Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. 2004 J. Dent. Res. pmid:14742657
Heim M et al. The phytoestrogen genistein enhances osteogenesis and represses adipogenic differentiation of human primary bone marrow stromal cells. 2004 Endocrinology pmid:14605006
Crotti TN et al. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. 2004 Biomaterials pmid:14607494
Vegni FE et al. Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis. 2004 N. Engl. J. Med. pmid:14711922
Crisafulli A et al. Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women. 2004 J. Clin. Endocrinol. Metab. pmid:14715848
Onyia JE et al. Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption. 2004 J. Pharmacol. Exp. Ther. pmid:14718597
Smith MD Comment on review on T cells in bone biology. 2004 Rheumatology (Oxford) pmid:15448222
Kubota A et al. Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts. 2004 J. Rheumatol. pmid:14994384
Kötter I and Stübiger N Therapeutic implications for interferon-alpha in arthritis. 2004 J. Rheumatol. pmid:14994421
Schett G et al. Soluble RANKL and risk of nontraumatic fracture. 2004 JAMA pmid:14996780
Tsuji K et al. Periodontal ligament cells under intermittent tensile stress regulate mRNA expression of osteoprotegerin and tissue inhibitor of matrix metalloprotease-1 and -2. 2004 J. Bone Miner. Metab. pmid:14999519
Jørgensen HL et al. Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios. 2004 J. Bone Miner. Metab. pmid:14999524
Lowe CE et al. Cost-effective analysis of candidate genes using htSNPs: a staged approach. 2004 Genes Immun. pmid:15029236
Brown JM et al. Opg, RANKl, and RANK in cancer metastasis: expression and regulation. 2004 Cancer Treat. Res. pmid:15043192
Tay JY et al. Identification of RANKL in osteolytic lesions of the facial skeleton. 2004 J. Dent. Res. pmid:15044512
Doran PM et al. Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts. 2004 Exp. Hematol. pmid:15050745
Kostenuik PJ et al. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. 2004 Bone pmid:15050896
Baek KH et al. Changes in the serum growth factors and osteoprotegerin after bone marrow transplantation: impact on bone and mineral metabolism. 2004 J. Clin. Endocrinol. Metab. pmid:15001618
Brage M et al. Osteoclastogenesis is decreased by cysteine proteinase inhibitors. 2004 Bone pmid:15003789
Fukunaga J et al. Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506. 2004 Bone pmid:15003790
Sattler AM et al. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. 2004 Calcif. Tissue Int. pmid:14523602
Bergh JJ et al. Osteoprotegerin expression and secretion are regulated by calcium influx through the L-type voltage-sensitive calcium channel. 2004 Endocrinology pmid:14525906
Skoumal M et al. Serum osteoprotegerin but not receptor activator of NF-kappaB ligand correlates with Larsen score in rheumatoid arthritis. 2004 Ann. Rheum. Dis. pmid:14722219
WÅ‚odarski KH et al. Influence of osteoprotegerin (OPG) on experimentally induced ectopic bone. 2004 Folia Biol. (Krakow) pmid:19058561
Saidenberg-Kermanac'h N et al. Role for osteoprotegerin in rheumatoid inflammation. 2004 Joint Bone Spine pmid:14769514
Abu-Amer Y et al. TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis. 2004 J. Cell. Biochem. pmid:15389885
Yang KC et al. [Effect of nylestriol and levonorgestrel on the expression of Opg/OPGL in human osteosarcoma MG-63 cell lines]. 2004 Zhong Nan Da Xue Xue Bao Yi Xue Ban pmid:16114553
Roux S and Mariette X The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression. 2004 Leuk. Lymphoma pmid:15359989
Wittrant Y et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. 2004 Biochim. Biophys. Acta pmid:15363860
Wada N et al. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. 2004 Bone pmid:15336598
Amato G et al. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. 2004 Bone pmid:15336617
Ono Y et al. Suppressive effect of Kanzo-bushi-to, a Kampo medicine, on collagen-induced arthritis. 2004 Biol. Pharm. Bull. pmid:15340228
Farach-Carson MC et al. Integrating rapid responses to 1,25-dihydroxyvitamin D3 with transcriptional changes in osteoblasts: Ca2+ regulated pathways to the nucleus. 2004 Steroids pmid:15288767
Vanderborght A et al. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls. 2004 J. Rheumatol. pmid:15290725
Soufi M et al. Osteoprotegerin gene polymorphisms in men with coronary artery disease. 2004 J. Clin. Endocrinol. Metab. pmid:15292302
Schoppet M et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis. 2004 J. Clin. Endocrinol. Metab. pmid:15292354
Lossdörfer S et al. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity. 2004 J Biomed Mater Res A pmid:15293309
Kondo T et al. 1 alpha,25 dihydroxyvitamin D3 rapidly regulates the mouse osteoprotegerin gene through dual pathways. 2004 J. Bone Miner. Res. pmid:15312241
Daroszewska A et al. Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin. 2004 J. Bone Miner. Res. pmid:15312251
Liu JM et al. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75]. 2004 Zhonghua Nei Ke Za Zhi pmid:15312444
Haynes DR Bone lysis and inflammation. 2004 Inflamm. Res. pmid:15693607
Kiefer JA et al. The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. 2004 Clin. Exp. Metastasis pmid:15672862
Xiao XH et al. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro]. 2004 Zhonghua Yi Xue Za Zhi pmid:15730627
Kostenuik PJ Revisiting the seed and soil theory of bone metastasis: new tools, same answer. 2004 J Musculoskelet Neuronal Interact pmid:15758267
Varga F et al. Triiodothyronine (T3) and 1,25-dihydroxyvitamin D3 (1,25D3) inversely regulate OPG gene expression in dependence of the osteoblastic phenotype. 2004 Calcif. Tissue Int. pmid:15255076
Miyashita T et al. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. 2004 Clin. Exp. Immunol. pmid:15270863
Nociti FH et al. Cementoblast gene expression is regulated by Porphyromonas gingivalis lipopolysaccharide partially via toll-like receptor-4/MD-2. 2004 J. Dent. Res. pmid:15271967
Hashimoto T et al. [Biochemical markers in bone metastasis]. 2004 Gan To Kagaku Ryoho pmid:15272580
Oh KW et al. The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women. 2004 Clin. Endocrinol. (Oxf) pmid:15272921
Doi S et al. Increased serum osteoprotegerin level in older and diabetic hemodialysis patients. 2004 Ther Apher Dial pmid:15274686
Stilgren LS et al. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. 2004 Bone pmid:15207766
Tsangari H et al. Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck. 2004 Bone pmid:15207775
Garlet GP et al. Matrix metalloproteinases, their physiological inhibitors and osteoclast factors are differentially regulated by the cytokine profile in human periodontal disease. 2004 J. Clin. Periodontol. pmid:15257746
Baumann B et al. Effects of polyethylene and TiAlV wear particles on expression of RANK, RANKL and OPG mRNA. 2004 Acta Orthop Scand pmid:15260421
Tomek S et al. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. 2004 Gynecol. Oncol. pmid:15262127
Bord S et al. Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen. 2004 Br. J. Haematol. pmid:15238146
Buxton EC et al. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). 2004 J. Clin. Endocrinol. Metab. pmid:15240611
Kochanowska I et al. Influence of osteoprotegerin (OPG) on resorption of heterotopically induced ossicle. 2004 Cell Tissue Bank pmid:15241009
Essalihi R et al. Phenotypic modulation of vascular smooth muscle cells during medial arterial calcification: a role for endothelin? 2004 J. Cardiovasc. Pharmacol. pmid:15838266
Ueland T et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. 2004 J. Am. Coll. Cardiol. pmid:15542278
Demer LL and Abedin M Skeleton key to vascular disease. 2004 J. Am. Coll. Cardiol. pmid:15542279
Vidal K et al. Osteoprotegerin production by human intestinal epithelial cells: a potential regulator of mucosal immune responses. 2004 Am. J. Physiol. Gastrointest. Liver Physiol. pmid:15521102
Pulsatelli L et al. Soluble receptor activator of nuclear factor- kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases. 2004 Biogerontology pmid:15105586
Hofbauer LC et al. Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid. 2004 Acta Neuropathol. pmid:15106011
Suzuki T et al. Osteoclastogenesis during mouse tooth germ development is mediated by receptor activator of NFKappa-B ligand (RANKL). 2004 J. Bone Miner. Metab. pmid:15108059
Gonzalez-Calvin JL et al. Bone mineral density and serum levels of estradiol and osteoprotegerin in postmenopausal women with viral cirrhosis. 2004 Gastroenterology pmid:15057779
Cheng Q et al. [Effect of osteoprotegerin gene polymorphism on bone mass in postmenopausal women]. 2004 Zhonghua Yi Xue Za Zhi pmid:15059506
Jang HD et al. PIAS3 suppresses NF-kappaB-mediated transcription by interacting with the p65/RelA subunit. 2004 J. Biol. Chem. pmid:15140884
Granet C et al. Increased AP-1 and NF-kappaB activation and recruitment with the combination of the proinflammatory cytokines IL-1beta, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes. 2004 Arthritis Res. Ther. pmid:15142264
Bengtsson AK et al. 17beta-estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells. 2004 Blood pmid:15142882
Golledge J et al. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. 2004 Stroke pmid:15143295
Seshasayee D et al. A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response. 2004 J. Biol. Chem. pmid:15145935
Yeung RS The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss. 2004 J. Rheumatol. pmid:15124240
Masi L et al. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury? 2004 J. Rheumatol. pmid:15124262
Nitta K et al. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. 2004 Nephrol. Dial. Transplant. pmid:15128884
Milstead JR et al. Spaceflight and hindlimb suspension disuse models in mice. 2004 Biomed Sci Instrum pmid:15133943
Su X et al. [Effects of parathyroid hormone on osteoprotegerin expression and osteoprotegerin ligand and their related cytokines in human osteoblasts]. 2004 Zhong Nan Da Xue Xue Bao Yi Xue Ban pmid:16137047
Chondrogianni N et al. Cloning of differentially expressed genes in skin fibroblasts from centenarians. 2004 Biogerontology pmid:15609104
Martinetti A et al. Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. 2004 Endocr. Relat. Cancer pmid:15613451
Whyte MP and Mumm S Heritable disorders of the RANKL/OPG/RANK signaling pathway. 2004 J Musculoskelet Neuronal Interact pmid:15615493
Hofbauer LC et al. The OPG/RANKL/RANK system in metabolic bone diseases. 2004 J Musculoskelet Neuronal Interact pmid:15615494
Ritchlin CT et al. RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis. 2004 J Musculoskelet Neuronal Interact pmid:15615495
Clohisy DR and Mantyh PW Bone cancer pain and the role of RANKL/OPG. 2004 J Musculoskelet Neuronal Interact pmid:15615497
Herrmann M and Herrmann W The assessment of bone metabolism in female elite endurance athletes by biochemical bone markers. 2004 Clin. Chem. Lab. Med. pmid:15576300
Jono S [Risk factors of atherosclerosis in end-stage renal disease patients]. 2004 Clin Calcium pmid:15576949
Shimizu M and Tamura T [Regulation of bone mineralization by parathyroid hormone]. 2004 Clin Calcium pmid:15577058
Wittrant Y et al. Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities. 2004 Exp. Cell Res. pmid:14729467
Hruska KA et al. Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy. 2004 Semin. Nephrol. pmid:14730507
Zwerina J et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. 2004 Arthritis Rheum. pmid:14730626
Mallat Z and Tedgui A Unbalanced RANKL/RANK pathway in aortic valve sclerosis. 2004 J. Mol. Cell. Cardiol. pmid:14734042
Kaden JJ et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. 2004 J. Mol. Cell. Cardiol. pmid:14734048
Itonaga I et al. Transforming growth factor-beta induces osteoclast formation in the absence of RANKL. 2004 Bone pmid:14751563
Pan B et al. The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). 2004 J. Bone Miner. Res. pmid:14753746
Valverde P et al. Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease. 2004 J. Bone Miner. Res. pmid:14753747
Buzi F et al. Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis. 2004 Clin. Endocrinol. (Oxf) pmid:14678293
Cheng X et al. Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo. 2004 J. Biol. Chem. pmid:14679212

Table of Content